

# James A Underberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5561730/publications.pdf>

Version: 2024-02-01

51  
papers

1,761  
citations

331259

21  
h-index

276539

41  
g-index

59  
all docs

59  
docs citations

59  
times ranked

2638  
citing authors

#	ARTICLE	IF	CITATIONS
1	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. <i>Journal of Clinical Lipidology</i> , 2015, 9, S1-S122.e1.	0.6	430
2	2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2013, 61, 992-1025.	1.2	148
3	2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery Disease. <i>Circulation</i> , 2013, 127, 1052-1089.	1.6	136
4	Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2017, 11, 880-890.	0.6	85
5	Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology. <i>Annals of Internal Medicine</i> , 2016, 165, 867.	2.0	84
6	Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry. <i>American Heart Journal</i> , 2014, 167, 342-349.e17.	1.2	76
7	<scp>PCSK9</scp> inhibitor access barriers issues and recommendations: Improving the access process for patients, clinicians and payers. <i>Clinical Cardiology</i> , 2017, 40, 243-254.	0.7	71
8	Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2020, 14, 398-413.	0.6	70
9	Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry. <i>Atherosclerosis</i> , 2017, 267, 19-26.	0.4	64
10	Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry. <i>Atherosclerosis</i> , 2019, 289, 85-93.	0.4	60
11	ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1336-1363.	1.2	50
12	Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER). <i>Journal of Clinical Lipidology</i> , 2020, 14, 807-817.	0.6	41
13	Systematic Review: Evaluating the Effect of Lipid-Lowering Therapy on Lipoprotein and Lipid Values. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 465-479.	1.3	38
14	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. <i>Atherosclerosis</i> , 2021, 319, 51-61.	0.4	37
15	LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design. <i>Journal of Clinical Lipidology</i> , 2016, 10, 273-282.	0.6	35
16	Lack of Pharmacokinetic Interactions Between Pitavastatin and Efavirenz or Darunavir/Ritonavir. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 67, 390-396.	0.9	32
17	Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels. <i>Journal of Clinical Lipidology</i> , 2017, 11, 450-458.e1.	0.6	28
18	ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease. <i>Circulation</i> , 2009, 120, e100-26.	1.6	25

#	ARTICLE	IF	CITATIONS
19	2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery Disease. <i>Critical Pathways in Cardiology</i> , 2013, 12, 65-105.	0.2	23
20	Characterization of PCSK9 in the Blood and Skin of Psoriasis. <i>Journal of Investigative Dermatology</i> , 2021, 141, 308-315.	0.3	23
21	Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: Proceedings from a workshop. <i>Journal of Clinical Lipidology</i> , 2013, 7, 573-609.	0.6	22
22	Cardiovascular Effects of the New Weight Loss Agents. <i>Journal of the American College of Cardiology</i> , 2016, 68, 849-859.	1.2	22
23	The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2017, 19, 48.	2.0	20
24	Resistant Hypertension and Sleep Apnea: Pathophysiologic Insights and Strategic Management. <i>Current Diabetes Reports</i> , 2011, 11, 64-69.	1.7	18
25	Cardiovascular Risk Factor Control and Lifestyle Factors in Young to Middle-Aged Adults with Newly Diagnosed Obstructive Coronary Artery Disease. <i>Cardiology</i> , 2019, 142, 83-90.	0.6	16
26	Laparoscopic gastric banding resolves the metabolic syndrome and improves lipid profile over five years in obese patients with body mass index 30-40 kg/m <sup>2</sup> . <i>Atherosclerosis</i> , 2014, 237, 183-190.	0.4	13
27	Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1177-1180.	0.6	13
28	Suboptimal risk factor control in patients undergoing elective coronary or peripheral percutaneous intervention. <i>American Heart Journal</i> , 2014, 168, 310-316.e3.	1.2	12
29	Prevalence of unrecognized diabetes, prediabetes and metabolic syndrome in patients undergoing elective percutaneous coronary intervention. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 603-609.	1.7	8
30	The Recent National Lipid Association Recommendations: How Do They Compare to Other Established Dyslipidemia Guidelines?. <i>Current Atherosclerosis Reports</i> , 2015, 17, 494.	2.0	7
31	Management of Hypogonadism in Cardiovascular Patients. <i>Urologic Clinics of North America</i> , 2016, 43, 247-260.	0.8	6
32	Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial. <i>American Heart Journal</i> , 2018, 199, 37-43.	1.2	6
33	Lowering LDL Cholesterol and CV Benefits: Is There a Limit to How Low LDL Needs to be for Optimal Health Benefits?. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 290-296.	2.3	6
34	JCL roundtable: Risk evaluation and mitigation strategy. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1288-1296.	0.6	5
35	A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-T Study. <i>Journal of the American Heart Association</i> , 2022, 11, e024176.	1.6	5
36	Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice. <i>Postgraduate Medicine</i> , 2016, 128, 31-39.	0.9	4

#	ARTICLE	IF	CITATIONS
37	LONG-TERM SAFETY AND EFFICACY OF LOMITAPIDE IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: THREE-YEAR DATA FROM THE LOMITAPIDE OBSERVATIONAL WORLDWIDE EVALUATION REGISTRY (LOWER). <i>Journal of the American College of Cardiology</i> , 2018, 71, A168.	1.2	4
38	JCL Roundtable: Global Think Tank on Lipoprotein(a). <i>Journal of Clinical Lipidology</i> , 2021, 15, 387-393.	0.6	4
39	The role of mipomersen therapy in the treatment of familial hypercholesterolemia. <i>Clinical Investigation</i> , 2012, 2, 1033-1037.	0.0	3
40	Genetic effects on efficacy of lipid-lowering drugs. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1112-1117.	0.6	2
41	Utility of Different Lipid Measures to Predict Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 35-6; author reply 36.	3.8	1
42	New Treatment Approaches for Dyslipidemia and its Management. <i>Current Cardiovascular Risk Reports</i> , 2013, 7, 395-400.	0.8	0
43	Relationship between plasma apolipoprotein B concentrations and LDL particle number. <i>Research Reports in Clinical Cardiology</i> , 0, , 237.	0.2	0
44	Niacin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients. <i>Contemporary Diabetes</i> , 2014, , 399-413.	0.0	0
45	The National Lipid Association's new recommendations for patient-centered management of cholesterol. <i>Clinical Lipidology</i> , 2015, 10, 13-15.	0.4	0
46	Developing Optimized Treatment Plans for Patients with Dyslipidemia in the Era of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapeutics. <i>American Journal of Medicine</i> , 2017, 130, 1233.	0.6	0
47	What is sufficient drug therapy for lipoprotein elevations?. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1300-1308.	0.6	0
48	Long-term Safety and Efficacy of Lomitapide in Patients with Homozygous Familial Hypercholesterolemia: Three-Year Data from LOWER. <i>Atherosclerosis Supplements</i> , 2018, 32, 24.	1.2	0
49	LDL-C Therapeutic Target Attainment in Patients with Homozygous Familial Hypercholesterolemia treated with Lomitapide. <i>Atherosclerosis Supplements</i> , 2018, 32, 153-154.	1.2	0
50	Long-term Liver Safety of Lomitapide in Patients with Homozygous Familial Hypercholesterolemia: Three-year Data from LOWER. <i>Atherosclerosis Supplements</i> , 2018, 32, 153.	1.2	0
51	Bridging the gap in treatment options for patients with hypertriglyceridemia. <i>Journal of Family Practice</i> , 2007, 56, S24-31.	0.2	0